CEL-SCI Corporation 10-Q Summary
Business Context and Reporting Period
Company: CEL-SCI Corporation (CEL-SCI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2008
Business Overview: CEL-SCI is a biopharmaceutical company focused on the development of Multikine (for cancer treatment) and L.E.A.P.S. technology. The company has not generated revenue from product sales and relies on financing activities to fund research and development (R&D) and operations. It operates a 73,000-square-foot manufacturing facility in Baltimore, Maryland, leased for 20 years.
Key Financial Metrics
| Metric | Q1 2009 (Ended Dec 31, 2008) | Q1 2008 (Ended Dec 31, 2007) |
|---|---|---|
| Total Revenue | $0 | $1,530 |
| Net Loss | $(1,950,986) | $(1,842,735) |
| Net Loss Per Share (Basic & Diluted) | $(0.02) | $(0.02) |
| Operating Cash Flow | $(1,159,800) | $(1,440,094) |
| Cash and Cash Equivalents (Ending) | $98,947 | $9,339,221 |
| Total Assets | $13,680,065 | $14,683,672 |
| Total Liabilities | $3,486,535 | $3,847,637 |
| Stockholders' Equity | $10,193,530 | $10,836,035 |
Debt and Liquidity:
- Convertible Debt (Series K): $1,875,716 principal remaining. Interest is payable in cash or stock.
- Short-term Loans: $100,000 related-party loan outstanding (15% interest, due March 2009).
- Derivative Liabilities: $2,305,657 (current portion) related to Series K warrants.
- Restricted Cash: $125,284.
Material Changes vs. Prior Period
- Revenue: Dropped to $0 from $1,530 in the prior year quarter. The company has no product sales revenue.
- Expenses:
- R&D Expenses: Increased by $159,260 (15.5%) to $1,188,226, driven by preparations for the Multikine Phase III clinical trial.
- General & Administrative (G&A): Decreased by $730,623 (41%) to $1,055,126. This reduction is primarily due to the absence of large non-recurring stock-based compensation expenses recorded in the prior year (option extensions and stock issuance costs).
- Cash Position: Cash and cash equivalents plummeted from $711,258 at the start of the quarter to $98,947 at period end, a decrease of $612,311. This was driven by operating losses and capital expenditures, partially offset by financing proceeds.
- Derivative Gains: Recorded a gain of $391,689 on derivative instruments (down from $989,988 in the prior year), resulting from fluctuations in the company's stock price affecting the fair value of Series K warrants.
Outlook, Risks, and Management Commentary
Liquidity and Capital Resources:
- The company faces significant liquidity constraints with only ~$99k in cash as of Dec 31, 2008.
- Management expects to raise additional capital in fiscal 2009 via corporate partnerships or equity financings to support operations and the Phase III trial.
- A $5 million Equity Line of Credit was established in December 2008, allowing the company to sell up to $5 million of stock over two years. No drawdowns occurred in this quarter.
- Management believes current cash, combined with expense reductions and the equity line, will sustain operations through March 2010, assuming debt holders do not exercise put options.
Operational Strategy:
- Phase III Trial: The company is delaying the start of the Multikine Phase III clinical trial until firm funding commitments are secured.
- Cost Reduction: The company is operating at significantly reduced cash expenditure levels. Large non-recurring expenses from the manufacturing facility build-out in 2008 will not recur in 2009.
- Contract Manufacturing: The company plans to offer contract manufacturing services in its new facility to generate cash flow.
Risks and Contingencies:
- Going Concern: Independent auditors issued a going concern opinion on the prior year's financials. The company must raise capital to continue operations.
- Lease Default Risk: In December 2008, the company failed to pay an installment of Base Annual Rent. The landlord has not declared formal default but has renegotiated terms, deferring 3 months of rent (Dec-Feb) to be paid after future financings. Failure to pay rent starting March 2009 constitutes a material default.
- Debt Repayment: Series K Note holders may require repayment of the entire remaining principal balance at any time after August 4, 2009. Repayment can be made in stock.
- Regulatory Approval: No assurance exists that the company will obtain FDA approval for Multikine or that clinical trials will be successful.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to secure financing before March 2009 to cover the deferred rent payments and ongoing operations, given the low cash balance of $98,947.
- Lease Compliance: Monitor the company's ability to resume rent payments in March 2009 to avoid a material default on the manufacturing facility lease.
- Debt Conversion: Assess the potential dilution impact if Series K Note holders exercise their option to convert debt to equity or if the company uses stock to repay interest/principal.
- Phase III Funding: Confirm the status of partnerships or financing deals intended to fund the Multikine Phase III clinical trial, which is currently on hold.
- Equity Line Utilization: Track whether the company utilizes the $5 million Equity Line of Credit and the resulting dilution to existing shareholders.